Karen Bernstein - Net Worth and Insider Trading
Karen Bernstein Net Worth
The estimated net worth of Karen Bernstein is at least $23,200 dollars as of 2024-09-20. Karen Bernstein is the Director of Ovid Therapeutics Inc and owns about 20,000 shares of Ovid Therapeutics Inc (OVID) stock worth over $23,200. Details can be seen in Karen Bernstein's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Karen Bernstein has not made any transactions after 2019-02-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Karen Bernstein
Karen Bernstein Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Karen Bernstein owns 4 companies in total, including Codiak BioSciences Inc (CDAKQ) , Ovid Therapeutics Inc (OVID) , and Achaogen Inc (AKAOQ) among others .
Click here to see the complete history of Karen Bernstein’s form 4 insider trades.
Insider Ownership Summary of Karen Bernstein
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CDAKQ | Codiak BioSciences Inc | 2020-10-13 | director |
OVID | Ovid Therapeutics Inc | 2019-02-26 | director |
AKAOQ | Achaogen Inc | 2018-06-05 | director |
2016-10-25 | director |
Karen Bernstein Latest Holdings Summary
Karen Bernstein currently owns a total of 1 stock. Karen Bernstein owns 20,000 shares of Ovid Therapeutics Inc (OVID) as of February 26, 2019, with a value of $23,200.
Latest Holdings of Karen Bernstein
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
OVID | Ovid Therapeutics Inc | 2019-02-26 | 20,000 | 1.16 | 23,200 |
Holding Weightings of Karen Bernstein
Karen Bernstein Form 4 Trading Tracker
According to the SEC Form 4 filings, Karen Bernstein has made a total of 0 transactions in Ovid Therapeutics Inc (OVID) over the past 5 years. The most-recent trade in Ovid Therapeutics Inc is the acquisition of 10,000 shares on February 26, 2019, which cost Karen Bernstein around $20,200.
Insider Trading History of Karen Bernstein
- 1
Karen Bernstein Trading Performance
GuruFocus tracks the stock performance after each of Karen Bernstein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Karen Bernstein is -23.73%. GuruFocus also compares Karen Bernstein's trading performance to market benchmark return within the same time period. The performance of stocks bought by Karen Bernstein within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Karen Bernstein's insider trading performs compared to the benchmark.
Performance of Karen Bernstein
Karen Bernstein Ownership Network
Karen Bernstein Owned Company Details
What does Codiak BioSciences Inc do?
Who are the key executives at Codiak BioSciences Inc?
Karen Bernstein is the director of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .
Codiak BioSciences Inc (CDAKQ) Insider Trades Summary
Over the past 18 months, Karen Bernstein made no insider transaction in Codiak BioSciences Inc (CDAKQ). Other recent insider transactions involving Codiak BioSciences Inc (CDAKQ) include a net sale of 41,667 shares made by Douglas E Williams , a net sale of 13,412 shares made by Linda Bain , and a net sale of 11,762 shares made by Sriram Sathyanarayanan .
In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 85,138 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 85,138 shares.
Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Codiak BioSciences Inc Insider Transactions
Karen Bernstein Mailing Address
Above is the net worth, insider trading, and ownership report for Karen Bernstein. You might contact Karen Bernstein via mailing address: C/o Vitae Pharmaceuticls, Inc., 502 West Office Center Drive, Fort Washington Pa 19034.